Skip to main content

Remote Job Finders (RJF)

As GLP-1s Hit Bargain Bin Prices, What’s the Future of the Obesity Market?

Novo Nordisk goes “on the offensive” following Trump deal that also included rival Eli Lilly, putting an exclamation point on rapidly declining GLP-1 drug prices. Experts say the unusual situation makes it hard to predict what’s next.

Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions

Drug candidates don’t usually move among Big Pharma, but these five biotechs helped facilitate such hand-offs, scooping up assets from one pharma on the cheap before being bought out for billions by another.

Before GLP-1s, a Great Pricing Battle Played Out in Hep C Market

The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C. A similar dynamic is now playing out between Eli Lilly and Novo Nordisk in the obesity space, with some key differences.
Scroll to top